ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
평활근육종 치료제 시장 규모는 앞으로 수년간 강력한 성장이 예상됩니다. 2029년 연평균 복합 성장률(CAGR)은 8.4%로 성장할 전망이며, 16억 3,000만 달러에 이를 전망입니다. 예측 기간의 성장은 면역요법에 따른 신약 후보의 채용 증가, 희소암 치료에서 유전체 및 분자 프로파일링 이용 확대, 희소약 파이프라인 및 규제지정 증가, 개인화 치료 전략에 대한 수요 증가, 환자 옹호 및 지원 네트워크의 강화에 기인할 것으로 보입니다. 이 기간에 예상되는 주요 동향으로는 기술 중심의 약물 스크리닝, 다중 타겟 치료법 개발, 유전체 데이터 치료 계획에 통합, 집학적 치료 모델 채택, 단일클론항체 치료법의 진보 등이 있습니다.
종양학 조사에 대한 투자 증가는 향후 수년간 같은 시장의 성장을 이끌 것으로 예측됩니다. 암 연구는 암의 원인, 연구 개발, 진단, 치료, 예방을 과학적으로 탐구하는 것입니다. 이러한 투자가 증가하고 있는 배경에는 세계 암 이환율 상승이 크게 기여하고 있습니다. 평활근육종 치료제의 개발은 표적치료의 기술 혁신을 촉진하고 희소암 치료의 진보를 위한 자금을 모으는 것으로 암 연구에 공헌하고 있습니다. 예를 들어 2023년 미국 방사선종양학회(ASTRO)는 미국 국립위생연구소(NIH)가 510억 달러의 자금을 획득했으며, 그 중 미국 국립암 연구소(NCI)가 99억 8,800만 달러로 전년도보다 27억 달러 증가했다고 보고했습니다. 따라서 종양학 연구에 대한 투자 증가는 평활근육종 치료제 시장의 성장에 중요한 역할을 합니다.
평활근육종 치료제 시장의 주요 기업은 루루비넥틴을 기반으로 하는 처방과 같은 혁신적인 표적 치료제 시장 개척에 주력하여 진행 종양 및 치료 저항성 종양 환자의 치료 성적을 향상시키고 있습니다. 루루비넥테진 기반의 요법은 평활근육종 세포를 특이적으로 공격하고 치료 효과를 향상시키기 위해 고안된 표적 항암제인 루루비넥테진을 사용합니다. 예를 들어, 2023년 10월, 스페인에 본사를 두고 있는 제약회사 Pharma Mar SA는 전이성 평활근육종(LMS) 환자에 대한 Zepzelca(루루비넥테진)와 독소루비신의 병용요법의 효능을 평가하는 SaLuDo 제IIb/III상 임상시험을 시작했습니다. 이 시험은 무증상 생존 기간 및 전체 생존 기간과 같은 주요 지표에 초점을 맞추어 병용 요법이 현재 치료 옵션에 비해 우수한 결과를 가져오는지 여부를 밝히는 것을 목표로 합니다. SaLuDo 시험이 성공하면 전이성 평활근육종과 싸우는 환자에게 새로운 희망을 가져오고 새로운 표준 치료가 될 수 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 평활근육종 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 평활근육종 치료제 시장 : 성장률 분석
세계의 평활근육종 치료제 시장 실적 : 규모 및 성장(2019-2024년)
세계의 평활근육종 치료제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 평활근육종 치료제 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 평활근육종 치료제 시장 : 약제 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
화학요법제
표적요법
면역요법
방사선치료
병용 요법
세계의 평활근육종 치료제 시장 : 약제 클래스별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
안트라 사이클린
알킬화제
대사 길항제
기타 약물 클래스
세계의 평활근육종 치료제 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
오랄
정맥내
피하
주제
근육내
세계의 평활근육종 치료제 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 평활근육종 치료제 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
연구실
재택 케어 설정
제약회사
세계의 평활근육종 치료제 시장 : 화학 요법제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
안트라 사이클린
알킬화제
대사 길항제
토포이소머라제 억제제
탁산
세계의 평활근육종 치료제 시장 : 표적요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
데옥시리보 핵산 마이너 그루브 바인더
티로신 키나아제 억제제
라파마이신 억제제의 메커니즘 표적
혈관 내피 증식 인자 억제제
세계의 평활근육종 치료제 시장 : 면역요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
면역관문 억제제
암 백신
입양 세포 이식
세계의 평활근육종 치료제 시장 : 방사선 치료 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
외부 방사선 치료
정위 방사선 치료
강도조절 방사선 치료
세계의 평활근육종 치료제 시장 : 병용 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
화학요법 표적요법
화학요법 방사선요법
면역요법 표적요법
제7장 지역별 및 국가별 분석
세계의 평활근육종 치료제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 평활근육종 치료제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
평활근육종 치료제 시장 : 경쟁 구도
평활근육종 치료제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson And Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck And Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
AstraZeneca Plc
Novartis AG
GlaxoSmithKline plc
Eli Lilly And Co
Philogen SpA
Eisai Co. Ltd
Incyte Corp
PharmaMar SA
Karyopharm Therapeutics Inc.
Taiho Pharmaceutical Co. Ltd.
Agenus Inc.
Adaptimmune Therapeutics plc
BioInvent International AB
Advenchen Laboratories LLC
Radiopharm Theranostics Limited
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
평활근육종 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
평활근육종 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
평활근육종 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Leiomyosarcoma drugs are pharmaceutical treatments specifically designed to manage or inhibit the progression of leiomyosarcoma, a rare type of cancer that arises from smooth muscle tissue. These drugs function by targeting the biological mechanisms that allow tumor cells to grow, multiply, and spread within the body.
The primary types of leiomyosarcoma treatments include chemotherapy agents, targeted therapies, immunotherapies, radiation therapies, and combination therapies. Chemotherapy agents are used to destroy or inhibit cancer cell growth by disrupting their division and multiplication processes. These agents belong to various classes, including anthracyclines, alkylating agents, antimetabolites, and others, and are administered through different routes such as oral, intravenous, subcutaneous, topical, and intramuscular methods. Distribution channels for these drugs include hospital pharmacies, retail pharmacies, online pharmacies, and others, catering to end users like hospitals, specialty clinics, research laboratories, homecare settings, and pharmaceutical companies.
The leiomyosarcoma drug market research report is one of a series of new reports from The Business Research Company that cover leiomyosarcoma drug market statistics, including the leiomyosarcoma drug industry's global market size, regional shares, competitors with the leiomyosarcoma drug market share, detailed leiomyosarcoma drug market segments, market trends and opportunities, and any further data you may need to thrive in the leiomyosarcoma drug market. This leiomyosarcoma drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The leiomyosarcoma drug market size has grown strongly in recent years. It will grow from $1.09 billion in 2024 to $1.18 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%./b> Growth during the historic period can be attributed to the rising incidence of uterine and soft tissue sarcomas, greater awareness among clinicians regarding rare cancers, increased patient participation in early-phase clinical trials, expanded off-label use of existing oncology drugs, and the growing utilization of radiologic imaging in cancer diagnostics.
The leiomyosarcoma drug market size is expected to see strong growth in the next few years. It will grow to $1.63 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%./b> Growth in the forecast period can be attributed to the increasing adoption of immunotherapy-based drug candidates, expanded use of genomic and molecular profiling in treating rare cancers, a growing pipeline of orphan drugs and regulatory designations, rising demand for personalized treatment strategies, and the strengthening of patient advocacy and support networks. Key trends expected during this period include technology-driven drug screening, the development of multi-targeted therapies, incorporation of genomic data into treatment planning, adoption of multidisciplinary care models, and advancements in monoclonal antibody therapies.
The increasing investment in oncology research is expected to drive the growth of the leiomyosarcoma drug market in the coming years. Oncology research involves the scientific exploration of the causes, development, diagnosis, treatment, and prevention of cancer. This growing investment is largely fueled by the rising global burden of cancer, which necessitates advanced therapies and better patient outcomes. The development of leiomyosarcoma drugs contributes to oncology research by promoting innovation in targeted treatments and attracting funding for advancements in rare cancer therapies. For example, in 2023, the American Society for Radiation Oncology (ASTRO) reported that the National Institutes of Health (NIH) received $51 billion in funding, including $9.988 billion for the National Cancer Institute (NCI), representing a $2.7 billion increase from the prior fiscal year. Thus, increasing investment in oncology research is playing a significant role in the growth of the leiomyosarcoma drug market.
Leading companies in the leiomyosarcoma drug market are concentrating on the development of innovative targeted therapies, such as lurbinectedin-based regimens, to enhance treatment outcomes for patients with advanced or treatment-resistant tumors. Lurbinectedin-based regimens involve the use of lurbinectedin, a targeted cancer drug designed to specifically attack leiomyosarcoma cells and improve therapeutic efficacy. For example, in October 2023, Pharma Mar S.A., a pharmaceutical company based in Spain, launched the SaLuDo Phase IIb/III clinical trial to assess the effectiveness of Zepzelca (lurbinectedin) in combination with doxorubicin for patients with metastatic leiomyosarcoma (LMS). This trial aims to determine whether the combination therapy offers superior results compared to current treatment options, focusing on key metrics such as progression-free survival and overall survival. If proven successful, the SaLuDo trial could set a new standard of care, offering new hope to patients battling metastatic leiomyosarcoma.
In December 2023, Pfizer Inc., a pharmaceutical company based in the United States, acquired Seagen Inc. for $43 billion. This acquisition is intended to bolster Pfizer's position in the oncology sector by utilizing Seagen's antibody-drug conjugate (ADC) technology to enhance its cancer treatment portfolio and support sustained revenue growth. Seagen Inc. is a U.S.-based biotechnology firm specializing in the development and commercialization of cancer therapies.
Major players in the leiomyosarcoma drug market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly And Co, Philogen S.p.A, Eisai Co. Ltd, Incyte Corp, PharmaMar SA, Karyopharm Therapeutics Inc., Taiho Pharmaceutical Co. Ltd., Agenus Inc., Adaptimmune Therapeutics plc, BioInvent International AB, Advenchen Laboratories LLC, and Radiopharm Theranostics Limited.
North America was the largest region in the leiomyosarcoma drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leiomyosarcoma drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the leiomyosarcoma drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The leiomyosarcoma drug market consists of sales of trabectedin, pazopanib, doxorubicin, gemcitabine, and eribulin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Leiomyosarcoma Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on leiomyosarcoma drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for leiomyosarcoma drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leiomyosarcoma drug market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: Chemotherapy Agents; Targeted Therapy; Immunotherapy; Radiation Therapy; Combination Therapy
2) By Drug Class: Anthracyclines; Alkylating Agents; Antimetabolites; Other Drug Class
3) By Route of Administration: Oral; Intravenous; Subcutaneous; Topical; Intramuscular
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
5) By End User: Hospitals; Specialized Clinics; Research Laboratories; Homecare Settings; Pharmaceutical Companies
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Leiomyosarcoma Drug Market Characteristics
3. Leiomyosarcoma Drug Market Trends And Strategies
4. Leiomyosarcoma Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Leiomyosarcoma Drug Growth Analysis And Strategic Analysis Framework
5.1. Global Leiomyosarcoma Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Leiomyosarcoma Drug Market Growth Rate Analysis
5.4. Global Leiomyosarcoma Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Leiomyosarcoma Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Leiomyosarcoma Drug Total Addressable Market (TAM)
6. Leiomyosarcoma Drug Market Segmentation
6.1. Global Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy Agents
Targeted Therapy
Immunotherapy
Radiation Therapy
Combination Therapy
6.2. Global Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anthracyclines
Alkylating Agents
Antimetabolites
Other Drug Class
6.3. Global Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Subcutaneous
Topical
Intramuscular
6.4. Global Leiomyosarcoma Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.5. Global Leiomyosarcoma Drug Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialized Clinics
Research Laboratories
Homecare Settings
Pharmaceutical Companies
6.6. Global Leiomyosarcoma Drug Market, Sub-Segmentation Of Chemotherapy Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anthracyclines
Alkylating Agents
Antimetabolites
Topoisomerase Inhibitors
Taxanes
6.7. Global Leiomyosarcoma Drug Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Deoxyribonucleic Acid Minor Groove Binders
Tyrosine Kinase Inhibitors
Mechanistic Target Of Rapamycin Inhibitors
Vascular Endothelial Growth Factor Inhibitors
6.8. Global Leiomyosarcoma Drug Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors
Cancer Vaccines
Adoptive Cell Transfer
6.9. Global Leiomyosarcoma Drug Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
External Beam Radiation Therapy
Stereotactic Body Radiation Therapy
Intensity-Modulated Radiation Therapy
6.10. Global Leiomyosarcoma Drug Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy + Targeted Therapy
Chemotherapy + Radiation Therapy
Immunotherapy + Targeted Therapy
7. Leiomyosarcoma Drug Market Regional And Country Analysis
7.1. Global Leiomyosarcoma Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Leiomyosarcoma Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Leiomyosarcoma Drug Market
8.1. Asia-Pacific Leiomyosarcoma Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Leiomyosarcoma Drug Market
9.1. China Leiomyosarcoma Drug Market Overview
9.2. China Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Leiomyosarcoma Drug Market
10.1. India Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Leiomyosarcoma Drug Market
11.1. Japan Leiomyosarcoma Drug Market Overview
11.2. Japan Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Leiomyosarcoma Drug Market
12.1. Australia Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Leiomyosarcoma Drug Market
13.1. Indonesia Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Leiomyosarcoma Drug Market
14.1. South Korea Leiomyosarcoma Drug Market Overview
14.2. South Korea Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Leiomyosarcoma Drug Market
15.1. Western Europe Leiomyosarcoma Drug Market Overview
15.2. Western Europe Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Leiomyosarcoma Drug Market
16.1. UK Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Leiomyosarcoma Drug Market
17.1. Germany Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Leiomyosarcoma Drug Market
18.1. France Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Leiomyosarcoma Drug Market
19.1. Italy Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Leiomyosarcoma Drug Market
20.1. Spain Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Leiomyosarcoma Drug Market
21.1. Eastern Europe Leiomyosarcoma Drug Market Overview
21.2. Eastern Europe Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Leiomyosarcoma Drug Market
22.1. Russia Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Leiomyosarcoma Drug Market
23.1. North America Leiomyosarcoma Drug Market Overview
23.2. North America Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Leiomyosarcoma Drug Market
24.1. USA Leiomyosarcoma Drug Market Overview
24.2. USA Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Leiomyosarcoma Drug Market
25.1. Canada Leiomyosarcoma Drug Market Overview
25.2. Canada Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Leiomyosarcoma Drug Market
26.1. South America Leiomyosarcoma Drug Market Overview
26.2. South America Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Leiomyosarcoma Drug Market
27.1. Brazil Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Leiomyosarcoma Drug Market
28.1. Middle East Leiomyosarcoma Drug Market Overview
28.2. Middle East Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Leiomyosarcoma Drug Market
29.1. Africa Leiomyosarcoma Drug Market Overview
29.2. Africa Leiomyosarcoma Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Leiomyosarcoma Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Leiomyosarcoma Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Leiomyosarcoma Drug Market Competitive Landscape And Company Profiles
30.1. Leiomyosarcoma Drug Market Competitive Landscape
30.2. Leiomyosarcoma Drug Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
31. Leiomyosarcoma Drug Market Other Major And Innovative Companies
31.1. AstraZeneca Plc
31.2. Novartis AG
31.3. GlaxoSmithKline plc
31.4. Eli Lilly And Co
31.5. Philogen S.p.A
31.6. Eisai Co. Ltd
31.7. Incyte Corp
31.8. PharmaMar SA
31.9. Karyopharm Therapeutics Inc.
31.10. Taiho Pharmaceutical Co. Ltd.
31.11. Agenus Inc.
31.12. Adaptimmune Therapeutics plc
31.13. BioInvent International AB
31.14. Advenchen Laboratories LLC
31.15. Radiopharm Theranostics Limited
32. Global Leiomyosarcoma Drug Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Leiomyosarcoma Drug Market
34. Recent Developments In The Leiomyosarcoma Drug Market
35. Leiomyosarcoma Drug Market High Potential Countries, Segments and Strategies
35.1 Leiomyosarcoma Drug Market In 2029 - Countries Offering Most New Opportunities
35.2 Leiomyosarcoma Drug Market In 2029 - Segments Offering Most New Opportunities
35.3 Leiomyosarcoma Drug Market In 2029 - Growth Strategies
